Biocytics

04/03/2026

Last week at the North Carolina Biotechnology Center (NCBiotech ), Dr. John Powderly II MD served as a keynote speaker at the "Hope is Not a Workflow" symposium which focused on advancing manufacturing for cell and gene therapy. 🧪

The initiative brings together developers, manufacturers, clinicians, patients, and regulators with a shared goal: to accelerate the delivery of safe, scalable, and accessible therapies.

Since our founding in 2005, Carolina BioOncology Institute (CBOI) and BioCytics has focused on advancing personalized immune cell approaches at the point of care, with a focus on research and pre-clinical development of new delivery models.

In 2026, hope alone is not enough for patients with metastatic cancer. Progress requires tangible change across the biopharma ecosystem, including new clinical delivery systems, innovative business models, and regulatory pathways that support point-of-care manufacturing.

A key part of this vision is a broader shift from cells as a drug product to cells as a patient-centered medical service, enabling more accessible and iterative innovation. We are proud to contribute to this ongoing conversation as the future of cell and gene therapy continues to evolve.

03/18/2026

Join us next week virtually or at the BioTech Center in RTP for an insightful session on advancing cell and gene therapy manufacturing. We’re excited to hear from Dr. John Powderly, our Founder and CEO, as he shares his vision for Carolina BioOncology Institute & Biocytics to bring individualized regenerative medicines to community-based clinical trial networks with point of care manufacturing at regional human application labs.

Together with industry leaders, we’ll explore how collaboration and ex*****on can accelerate life-changing treatments from discovery to patients.

💡 Free registration, secure your spot now: https://hopeisnotaworkflow.com/

03/18/2026

03/11/2026

🚀 Big news at BioCytics! We’re thrilled to welcome Dr. Koray Atalag and Dr. Colby Ford to our Informatics Advisory Board.

Their expertise in digital health, genomics, and cloud AI will help drive innovation in autologous cell therapy and precision oncology.

Please join us in giving them a warm welcome! 💙

02/20/2026

The BioCytics Human Applications Laboratory is hosting a 10 week paid Summer 2026 Internship in Huntersville, North Carolina. 🧪

This full time internship includes direct mentorship from BioCytics scientists and completion of an independent research project aligned with our mission to advance cellular therapies and personalized medicine for cancer.

📅 June 1 – August 10, 2026 (flexible dates)
🔬 Focus: Oncology immunotherapy research supporting our product pipeline
🎓 Seeking Junior, Senior, or Masters level students with a background in immunology or related sciences
🧬 Bench research experience and familiarity with flow cytometry preferred

To apply, email your resume with the subject line BioCytics 2026 Summer Internship to biocyticsinternships@biocytics.com
Applications accepted through March 31.

02/17/2026

In honor of the heart behind the research, here is a little science inspired appreciation from BioCytics and Carolina BioOncology Institute.

What we love about research is curiosity, collaboration, and the relentless pursuit of better answers. That is why innovation is built on people who care deeply about discovery.

01/30/2026

Our very own founder and president, Dr. John Powderly, advocates for a paradigm shift towards personalized medicine at the point of care, enabled by openEHR to overcome data silos and inefficiencies in cancer research. The goal is to ultimately improve patient access, affordability, and treatment outcomes by integrating regulatory data standards into openEHR.

Check out the full video at

Dr John Powderly (Carolina BioOncology Institute & BioCytics Human Applications Lab) presenting at openEHR's EHRCON25 in Barcelona - 'Embedding phase 1 cance...

01/25/2026

At BioCytics, collaboration is essential to advancing the future of cancer diagnostics and cell based innovation.

We recently collaborated with Kidod Science and Therapeutics to explore the potential of saliva based technologies for cancer detection and multi cancer early detection research. This work reflects our commitment to evaluating emerging diagnostic approaches and partnering with innovators to expand the possibilities of early cancer detection and advance cancer research.

Through strategic scientific partnerships, BioCytics continues to explore novel technologies that support translational research and the future of precision oncology. We welcome opportunities to collaborate with researchers and organizations who share our mission to push cancer science forward - reach out to learn more!

01/23/2026

Innovation at BioCytics is driven by continuous learning and technology evaluation. We recently welcomed Cytiva for an on site lunch and learn focused on the Sepax system's BeadWash application and Sefia Select magnetic selection platform for cell therapy manufacturing.

These discussions support our efforts to optimize cell processing workflows and evaluate tools that strengthen our autologous cell therapy development pipeline. We value industry partnerships that help advance efficient and scalable solutions.

12/27/2025

🎄 Wishing our partners, collaborators, and scientific community a peaceful holiday season and an exciting start to 2026.

🚀 BioCytics 2025: Year in Review
• Progress in autologous cell therapy development
• Expansion of biobank, biospecimen sourcing, and R&D capabilities
• Strengthened collaborations with biotech, academic, and clinical teams
• Continued growth of our technology platform
• FDA INTERACT meeting for BCyIF1 completed
• Celebrated 20-year anniversary

Thank you for supporting our mission to accelerate next-generation cell therapies. Here’s to a groundbreaking new year!

12/22/2025

During SITC 2025, our Founder and CEO, Dr. John Powderly, had the opportunity to meet with Dr. Peter Marks, MD, PhD, where they connected over their shared passion for advancing oncology research. It was an honor to discuss the future of immune cell therapies manufactured at the point of care, an area where both BioCytics and Carolina BioOncology Institute remain deeply committed to driving innovation.

We also extend our congratulations to Dr. Marks on receiving the SITC 2025 Innovation Award in recognition of his impactful contributions to the field of immunotherapy.

12/19/2025

🌍 In October, our IT team attended EHRCon 2025 in Barcelona, where global experts explored the evolving world of electronic health records (EHRs), artificial intelligence (AI), and open standards.

John Powderly II, MD, representing Carolina BioOncology Institute and BioCytics, presented how openEHR enables the seamless integration of electronic data capture, laboratory information management systems (LIMS), clinical trial management, and patient EHRs into a unified information ecosystem. This model propels precision medicine forward and lays the foundation for Real-Time Adaptive Clinical Trials, a transformative approach that uses individual patient clinical evidence to continuously improve treatment outcomes for all.

Collaboration, standardization, and innovation remain at the heart of turning clinical data into actionable insights for better patient care.